Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TYMS | P04818 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | DHFR | P00374 | 8/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pteropterin SCHEMBL8991 | 1.00 | KDM4E (0.69) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL12148554 | 0.97 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL3878 | 0.97 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL6470174 | 0.97 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL29677832 | 0.97 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL23388805 | 0.96 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL1887022 | 0.96 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL22441084 | 0.96 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL19837676 | 0.96 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL4406476 | 0.96 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23981 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694935-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-1083896-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000054795-A1 | COMBINED THERAPY WITH A CHEMOTHERAPEUTIC AGENT AND AN ONCOLYTIC VIRUS FOR KILLING TUMOR CELLS IN A SUBJECT | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1998037898-A1 | SYNERGISTICALLY ACTING ANTI-FUNGAL AGENTS THAT ARE INHIBITORS OF FOLATE METABOLISM, ESPECIALLY METHOTREXATE AND SULFAMETHOXAZOLE | BARCLAY BARRY J (CA) | 1998-09-03 | — | — | WO | claimed |
| EP-0641193-A4 | CHEMOTHERAPEUTIC DRUG COMBINATIONS. | MARTIN DANIEL S (US) | 1995-09-06 | — | — | EP | claimed |
| EP-0641193-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | PRO-NEURON, INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023014-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | MARTIN DANIEL S (US) | 1993-11-25 | — | — | WO | claimed |